TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cadrenal Therapeutics, Inc. ( (CVKD) ) has shared an announcement.
On September 24, 2025, Cadrenal Therapeutics, Inc. held its annual stockholders meeting where two key proposals were voted on. The first proposal resulted in the election of Steven Zelenkofske as a Class III director, set to serve until the 2028 annual meeting. The second proposal saw the ratification of WithumSmith+Brown, P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Average Trading Volume: 31,200
Technical Sentiment Signal: Hold
Current Market Cap: $28.21M
For an in-depth examination of CVKD stock, go to TipRanks’ Overview page.